Aims: The understanding of second-line use of glucose-lowering drugs (GLDs) in the general population with type 2 diabetes (T2D) treatment is important as recent results have shown cardiovascular benefits with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). Our aim was to describe second-line GLD treatment patterns in four Nordic countries. Results: A rapid uptake of newer GLDs (GLP-1RA, DPP-4i and SGLT-2i) over the 10-year observation period was seen in Denmark, Finland and Norway, while slower in Sweden. In 2015, 33,880 (3.1%) of 1,078,692 T2D patients initiated second-line treatment, and newer GLDs were more commonly used in Finland (92%), Norway (71%) and Denmark (70%) vs Sweden (44%). In 2015, the use of older GLDs (insulin and sulphonylureas) was 7-fold greater in Sweden compared to Finland (49% vs 7%), and 1.6-fold greater compared with Denmark and Norway (49% vs 30% and 29%, respectively).
| INTRODUC TI ON
For several years, global guidelines have advocated metformin as first-line pharmacological treatment of type 2 diabetes (T2D), but second-line treatment choices are considered equal and open for individualization based on choices and considerations among patients and healthcare professionals. 1 However, due to variances in reimbursement and national guidelines, there may well be differences between prescription patterns between countries.
Knowledge of second-line treatment patterns has become even more important as recent studies have reported secondary preventive cardiovascular (CV) benefits of several of the new glucoselowering drugs (GLDs). [2] [3] [4] [5] [6] [7] [8] Moreover, large observational studies have recently shown associations with increased risk of severe hypoglycaemia, CV and all-cause mortality with older GLDs (sulphonylureas and insulins) in second-line treatment. [9] [10] [11] [12] [13] [14] [15] [16] Consequently, there are large differences with regard to potential effects and side effects, drug administration, costs and evidence grades for the six different GLD classes currently recommended as second-line options, that is dipeptidyl peptidase-4 inhibitors (DPP-4is), sodium-glucose cotransporter-2 inhibitors (SGLT-2is), glucagon-like peptide-1 receptor agonists (GLP-1RA), sulphonylureas, thiazolidinediones and insulins. 1 An important first step is to understand to which extent different second-line GLDs are used in the broad T2D population, to determine inertia to follow new guidelines and willingness taking newer drugs into use.
The aim of this study was to describe second-line treatment after metformin monotherapy in four Nordic countries during the last decade using nationwide registers (covering a total population of >25 million inhabitants), and to examine potential treatment differences between the neighbouring countries.
| MATERIAL AND ME THODS

| Data sources
The present work is part of the D360 Nordic programme, a largescale diabetes investigation program which utilizes the unique features of full coverage nationwide healthcare registries and public healthcare systems covering more than 25 million inhabitants in all the Nordic countries, to include all T2D patients with filled GLD prescriptions. 17 Detailed data on the data sources, see Supporting
Information Appendix S1-section 1. 
| Study population
All T2D patients aged 18 years and above who filled a GLD prescription from the beginning of year 2006 to the end of year 2015 were included. Patients with a diagnosis of type 1 diabetes, gestational diabetes or polycystic ovarian syndrome were excluded (Supporting Information Appendix S1-section 2).
Second-line treatment was defined as ≥6 months (two reiteration prescription cycles of 3 months) of metformin monotherapy (at any dose), followed by a filled prescription of a second GLD class such as DPP-4i, SGLT-2i, GLP1-RA, sulphonylurea, insulin or other GLD (glitazones, acarbose and glinides). The index date was defined as the date of first filled prescription of the second-line drug.
| Baseline data
Patient characteristics included age at index date, sex, index date, date of first-line metformin GLD dispense and information on patient frailty (defined as at least one hospitalization of three or more consecutive days during the year prior to index date), detailed in Supporting Information Table S1b . 10, 13, 20 Comorbidities were searched for in all available data prior to and including the index date, with an exception for severe hypoglycaemia (within 12 months prior to index date) and cancer (within 5 years prior to index date), detailed Supporting Information Table S1c .
Prior medications were defined as any dispense 12 months prior to and including index date, detailed Supporting Information Table S1d .
| Statistical analysis
Demographic data are presented as mean (SD) or n (% 
| Second-line treatment from year 2006 to 2015
The second-line treatment patterns of filled GLD prescriptions showed rapid changes during the observation period years 2006-2015 in Finland, Denmark and Norway, whereas the uptake of the newer GLDs (DPP-4i, SGLT-2i and GLP1-RA) was slower in Sweden ( Figure 1) . Conversely, the use of sulphonylurea decreased substantially and insulin use remained low over the last decade in Finland, Denmark and Norway. This is in contrast to Sweden, where the use of both sulphonylurea and insulin remained at a higher level and started to decrease much later compared to the other Nordic countries.
| Second-line treatment year 2015
In 2015, second-line treatment is initiated after about 5 years (4.7- 
| Regional differences in second-line treatment within Sweden
In 2015, there was a large difference in use of newer GLDs as secondline treatment between "high and low user" counties in Sweden.
The highest use was found in Värmland (80%), Halland (67%) and Örebro (64%), whereas Gotland (25%), Norrbotten (25%) and Västra Götaland (29%) were at the lower end. Overall, the regional use of older GLDs displayed opposite differences to the above as ex- 
| D ISCUSS I ON
In national T2D populations, covering more than one million pharmacologically treated patients, we found that approximately 3%
were annually initiated on second-line treatment after metformin monotherapy, an observation that was consistent across the four All four Nordic countries have public healthcare systems that guarantee all citizen access to relevant care, treatment and reimbursed drugs. The health care is typically divided into a large primary sector, and a more specialized secondary sector including outpatient clinics and hospitals. For a chronic condition as T2D, initial treatment and prescriptions will be made by the primary care physician, and later it may be relevant to refer the patient to a specialized outpatient clinic. It can therefore be assumed the majority of decisions regarding second-line treatment are made in the primary care, and comparisons in our analysis are in fact mostly dependent on differences in organization and reimbursement of GLDs in the four countries. Interestingly, a similar fraction of the T2D population in each country was initiated on second-line therapy (approximately 3.2%) in 2015, perhaps indicating similarities in patient and physicians' treatment habits across the countries. In a recent comparison between a primary care database in the UK and a primary care and internal medicine database in Germany, distinctly different patterns of second-line treatment prescriptions were found in 10 000 patients. 25 In the German population, metformin was most frequently combined with DPP-4i, whereas 57% of the included UK population commonly have trained staff available to handle initiation of insulin therapy. 13, 28 The higher use of statin in Denmark despite the least prevalent CVD population might also reflect the differences in organization and attitudes on CV prevention in T2D across countries.
Finally, it is possible that there are country-specific differences to the various well-known barriers to treatment intensification, that is barriers to insulin initiation or addition of more drugs, equally frequent in patients and healthcare professionals, as reviewed by
Khunti et al 29 Apart from the prescription patterns of GLDs, we found an interesting difference in use of cardiovascular preventive drugs (reninangiotensin system blocking treatment, statins, low-dose aspirin and beta blockers) across the Nordic countries, which were lower in Norway (80%) as compared with the other three countries (89%-90%). Differences in implementation of multifactorial risk factor management or attitudes towards polypharmacy could be an explanation, but our data limit the conclusions that can be made.
The differences seen in our analyses may have a potential impact on both clinical outcomes and overall healthcare costs in the four countries, now and in the future. Adherence to guidelines using a multifactorial intervention strategy, based on the findings in the Steno 2 Study, has the potential to prolong survival and reduce the extent and cost of complications. 30 In addition, following 
| Limitations
This analysis is based on registries and therefore carries some limitations relating to the completeness and quality of the registries. Also, there may be some differences between registers from the four countries, although we have done our best to equalize any differences known. Particularly differences in classification of diabetes type may influence observed differences in, for example, insulin use.
Since there are no ICD-10 codes for Latent autoimmune diabetes of adults (LADA) diagnosis, it is difficult to determine the proportion of patients in any of the countries. With relatively low proportion of LADA patients and probably similar prevalence in the countries, we suggest that this has little impact when comparing treatment patterns. However, we cannot rule out that patients with early failure on metformin and/or second-line insulin treatment could harbour a higher proportion of LADA patients.
From our analysis, we can only determine which prescriptions were filled at the pharmacy, which does not equal actual ingestion of the drug. As such, we have no information on medication adherence once picked up from the pharmacy. In order to reliably define an established metformin monotherapy, we required at least two dispenses over 6 months since the reiteration cycle is 3 months. This means that second-line index earlier than 6 months will not be reflected in the results. It is not possible in this descriptive analysis to analyse the actual cause for the differences seen, as many different factors seem to interact. The present work has no information on laboratory measurements, lifestyle parameters, primary healthcare data, or socioeconomic data, and consequently, there may be remaining explanatory factors for choosing GLDs. However, in a representative subsample in Denmark,
Norway and Sweden from the D360 program, we found similar relevant laboratory measurements when comparing the three countries which could support similar blood glucose targets of the T2D patients. 
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